Post-meal β-cell function predicts the efficacy of glycemic control in patients with type 2 diabetes inadequately controlled by metformin monotherapy after addition of glibenclamide or acarbose

Table 4 Multiple linear regression models of HbA _1c after combination therapy

	Model 1		Model 2		Model 3
	β	P	β	P	β	P
Drug group (0 = glibenclamide; 1 = acarbose)	0.089	0.410	0.152	0.127	0.145	0.126
Gender (0 = female; 1 = male)	−0.163	0.110	-	-	-	-
Age (years)	−0.106	0.307	-	-	-	-
Disease duration (years)	0.105	0.313	-	-	-	-
BMI (kg/m²)	0.172	0.179	-	-	-	-
HbA_1c (%)	0.677	<0.001*	0.687	<0.001*	0.703	<0.001*
MISI	0.162	0.391	0.217	0.234	-	-
HOMA-IR	−0.305	0.080	−0.210	0.148	−0.244	0.085
HOMA-β (%)	−0.030	0.864	0.029	0.835	-	-
Insulinogenic index₃₀ (pmol/mmol)	−0.072	0.734	-	-	-	-
AUC_ins₁₂₀/AUC_{glu 120}^§(pmol/mmol)	0.301	0.258	0.302	0.150	0.158	0.249
DI₁₂₀	−0.801	0.045*	−0.743	0.031*	−0.552	0.030*
DI₃₀	0.456	0.226	0.329	0.176	0.284	0.142

Multiple linear regression models with HbA_1c after combination therapy as the dependent variable. All independent variables were collected before randomization of the second-line OADs.
*P < 0.005; § total area under curve of insulin within 120 minutes divided by total area under curve of glucose within 120 minutes.
DI, disposition index; HOMA-β, homeostasis model assessment β-cell function; HOMA-IR, homeostasis model assessment insulin resistance index;
Incremental AUC, incremental area under curve during liquid mixed meal tolerance test; MISI, Matsuda insulin sensitivity index.

ISSN: 1758-5996